Guinea-pig antisera are prepared by inoculating guinea pigs with 146S antigen of each serotype.
The guinea pig DNA and protein are useful for the development of models of human platelet aggregation.
Provided herein are novel nucleic acid and amino acids sequences of a phosphoprotein derived from a Guinea pig.
For a non-adjuvant Guinea pig test method a response of at least 15 % of the animals is considered positive.
In case the LLNA cannot be conducted, a justification shall be provided and the Guinea Pig Maximisation Test shall be performed.
The Guinea-Pig Maximisation Test (Gpmt) and the Buehler test are described in this method.
After washing, 50 μl of guinea-pig antiserum to the antigen used in point 4 is added to each well.
The principle of the test is the interruption of the reaction between AHSV antigen and a guinea-pig antiserum by a test serum sample.
The method includes the steps of determining an interhemispheric switch rate of the test subject.
This method is particularly useful for predicting drug interaction using a model organism.
Disclosed is a method for expressing hepatitis C virus in an in vivo, animal model.
The present invention provides a non-human model system for graft-versus-host disease.
Acetylsalicylic acid, a nonspecific cyclooxygenase inhibitor, was also found to suppress viral reactivation in the heat-stressed mouse model.
In a preferred embodiment, the interhemispheric switch rate is determined by measuring the rate of binocular rivalry in the test subject.
A method and apparatus for diagnosing schizophrenia, schizophrenia disorder subgroup, or predisposition thereto in a test subject is disclosed.
This model animal is useful in, for example, search and development of remedies for diseases associated with the sustained acceleration of blood coagulation.
The recipient and donor mammals can be from the same species or from different species such as a human recipient and a miniature swine donor.
The animal model for testing such compounds is the Sod2CJE homozygous Manganese Superoxide Dismutase-deficient mouse.
The invention additionally provides an animal model of AD and methods of screening for agents useful in the treatment, amelioration, or prevention of AD.
The model provides a preclinical system in which a population of donor CD8+ T cells that recognizes recipient alloantigens, can be distinguished from other T cell populations in the recipient animal.
With this model various features of GVHD can be studied including, for example, the involvement of inflammatory mediators, memory T cells, and CD4+ T cells in the pathogenesis of GVHD.